Atagabalin
Atagabalin (PD 0200390) is a Voltage-gated Calcium channel α2δ subunit binder with an IC50 of 22 nM. Atagabalin regulates neurotransmitter release by inhibiting calcium influx at high neuronal firing rates. Atagabalin can be used in research related to sleep disorders.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 223445-75-8
- Formule: C10H19NO2
- Masse moléculaire:185.26
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform Calcium Channel
More
Activité biologique
|
Calcium Channel |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
10 μM
Compound: 5
|
Inhibition of L-type amino acid transporter expressed in CHO cells assessed as inhibition of [3H]leucine uptake
Inhibition of L-type amino acid transporter expressed in CHO cells assessed as inhibition of [3H]leucine uptake
|
[PMID: 20005103] |
Atagabalin potently binds to the VGCC α2δ subunit with an IC50 of 22 nM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 223445-75-8
-
Masse moléculaire 185.26
-
Formule C10H19NO2
-
SMILES
O=C(O)CC1(CN)C[C@H](C)[C@@H](C)C1
-
Synonyms
PD 0200390
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Kjellsson MC, et al. Modeling sleep data for a new drug in development using markov mixed-effects models. Pharmaceutical research. 2011 Oct;28(10):2610-27. [Content Brief]
[2]. Corrigan B, et al. Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit. British journal of clinical pharmacology. 2009 Aug;68(2):174-80. [Content Brief]
[3]. Chen Y, et al. Review of Voltage-gated Calcium Channel α2δ Subunit Ligands for the Treatment of Chronic Neuropathic Pain and Insight into Structure-activity Relationship (SAR) by Pharmacophore Modeling. Current medicinal chemistry. 2022 Aug 15;29(30):5097-5112. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Atagabalin Related Classifications
HY-14856 Related Classifications
Powered by Bioz
- Atagabalin
- 223445-75-8
- PD 0200390
- PD0200390
- PD-0200390
- Calcium Channel
- renal excretion
- neurotransmitter release
- calcium channel α2δ subunit
- insomnia
- sleep disturbance
- slow-wave sleep
- rapid eye movement sleep
- pharmacophore modeling
- voltage-gated calcium channel alpha-2-delta subunits
- calcium influx
- Inhibitor
- inhibitor
- inhibit